Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

13.16
+0.73005.87%
Post-market: 13.210.0524+0.40%19:56 EDT
Volume:7.07M
Turnover:93.15M
Market Cap:10.50B
PE:-11.77
High:13.53
Open:12.69
Low:12.57
Close:12.43
52wk High:30.05
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:0.98
T/O Rate:4.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:16.66
PE(LYR):-9.11

Loading ...

Summit Therapeutics falls -8.5%

TIPRANKS
·
Aug 17

EV targets set to be watered down

cityam
·
Aug 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO), Summit Therapeutics (SMMT) and Altimmune (ALT)

TIPRANKS
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Summit Partner Akeso Wins China NMPA Approval for Ivonescimab-Chemo in First-Line Squamous NSCLC

Reuters
·
Aug 12

Summit Gains After Partner Akeso Secures China Nod for Lung Cancer Combo

Reuters
·
Aug 12

Ivonescimab in Combination with Chemotherapy Approved in China by Nmpa for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Aug 12

Summit Therapeutics Inc. : Leerink Partners Raises to Market Perform from Underperform; Raises Target Price to $13 from $12

THOMSON REUTERS
·
Aug 12

China's Automakers Capture Three Spots in UK July Best-Selling Top Ten

Deep News
·
Aug 06

Barclays Remains a Hold on Summit Therapeutics (SMMT)

TIPRANKS
·
Aug 06

Summit announces expansion of development program for ivonescimab

TIPRANKS
·
Aug 05

Summit Therapeutics - Initiates Global Phase Ii/Iii Harmoni-Gu1 Trial of Ivonescimab in Bladder Cancer

THOMSON REUTERS
·
Aug 05

Miliband refused to meet motor trade body to discuss zero emissions mandate

cityam
·
Jul 30

Vehicle production drops in first half of year

cityam
·
Jul 30

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Argenx Se (ARGX)

TIPRANKS
·
Jul 29

Analysts Conflicted on These Healthcare Names: HCA Healthcare (HCA), Summit Therapeutics (SMMT) and Neuphoria Therapeutics (NEUP)

TIPRANKS
·
Jul 27

Summit Therapeutics (SMMT) Updates Ivonescimab Progress, Is The 52% Undervalued View Convincing?

Simply Wall St.
·
Jul 27

Summit Therapeutics Faces Serious Going-Concern Risk as Cash Shortfall Threatens Operations

TIPRANKS
·
Jul 25

Summit Therapeutics Flags Going Concern Risk Over Cash Needs

Benzinga Earnings
·
Jul 24

U.S. Stocks on the Move-booz Allen Hamilton, Sensient, Amkor

Reuters
·
Jul 24